Jentzen Walter, Weise Reiner, Kupferschläger Jürgen, Freudenberg Lutz, Brandau Wolfgang, Bares Ronald, Burchert Wolfgang, Bockisch Andreas
Klinik für Nuklearmedizin, Universität Duisburg-Essen, Hufelandstrasse 55, Essen, Germany.
Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):611-23. doi: 10.1007/s00259-007-0554-7. Epub 2007 Oct 10.
This study evaluated the absolute quantification of iodine-124 ((124)I) activity concentration with respect to the use of this isotope for dosimetry before therapies with (131)I or (131)I-labeled radiotherapeuticals. The recovery coefficients of positron emission tomography(/computed tomography) PET(/CT) systems using (124)I were determined using phantoms and then validated under typical conditions observed in differentiated thyroid cancer (DTC) patients.
Transversal spatial resolution and recovery measurements with (124)I and with fluorine-18 ((18)F) as the reference were performed using isotope-containing line sources embedded in water and six isotope-containing spheres 9.7 to 37.0 mm in diameter placed in water-containing body and cylinder phantoms. The cylinder phantom spheres were filled with (18)F only. Measurements in two-dimensional (2D) and three-dimensional (3D) modes were performed using both stand-alone PET (EXACT HR(+)) and combined PET/CT (BIOGRAPH EMOTION DUO) systems. Recovery comparison measurements were additionally performed on a GE ADVANCE PET system using the cylinder phantom. The recovery coefficients were directly determined using the activity concentration of circular regions of interest divided by the prepared activity concentration determined by the dose calibrator. The recovery correction method was validated using three consecutive scans of the body phantom under our (124)I PET(/CT) protocol for DTC patients.
Compared with that of (18)F, transversal spatial resolution of (124)I was slightly, but statistically significantly degraded (7.4 mm vs. 8.3 mm, P<0.002). Using the body phantom, recovery was lower for (124)I than for (18)F in both 2D and 3D modes. The (124)I recovery coefficient of the largest sphere was significantly higher in 2D than in 3D mode (81% vs. 75%, P=0.03). Remarkably, the (18)F recovery coefficient for the largest sphere significantly deviated from unity (range of 87%-93%, P<0.004) for all scanners but the GE ADVANCE. The maximum range of inaccuracy of the measured (124)I activity concentration under in vivo conditions after applying partial volume correction was +/-10% for spheres > or =12.6 mm in diameter.
Recovery correction is mandatory for (124)I PET quantification, even for large structures. To ensure accurate dosimetry, thorough absolute recovery measurements must be individually established for the particular PET scanner and radionuclide to be used.
本研究评估了碘-124(¹²⁴I)活度浓度的绝对定量,该研究涉及在使用¹³¹I或¹³¹I标记的放射治疗药物进行治疗之前,将这种同位素用于剂量测定的情况。使用体模确定了使用¹²⁴I的正电子发射断层扫描/计算机断层扫描(PET/CT)系统的恢复系数,然后在分化型甲状腺癌(DTC)患者观察到的典型条件下进行验证。
使用嵌入水中的含同位素线源以及放置在含水人体和圆柱体模中的六个直径为9.7至37.0 mm的含同位素球体,以¹²⁴I和氟-18(¹⁸F)作为参考进行横向空间分辨率和恢复测量。圆柱体模球体仅填充¹⁸F。使用独立的PET(EXACT HR(+))和组合的PET/CT(BIOGRAPH EMOTION DUO)系统在二维(2D)和三维(3D)模式下进行测量。另外,使用圆柱体模在GE ADVANCE PET系统上进行恢复比较测量。使用感兴趣圆形区域的活度浓度除以剂量校准器确定的制备活度浓度直接确定恢复系数。使用我们针对DTC患者的¹²⁴I PET/CT方案对人体模进行连续三次扫描,验证恢复校正方法。
与¹⁸F相比,¹²⁴I的横向空间分辨率略有下降,但在统计学上有显著差异(7.4 mm对8.3 mm,P<0.002)。在人体模中,¹²⁴I在2D和3D模式下的恢复均低于¹⁸F。最大球体的¹²⁴I恢复系数在2D模式下显著高于3D模式(81%对75%,P=0.03)。值得注意的是,除GE ADVANCE外,所有扫描仪最大球体的¹⁸F恢复系数均显著偏离1(范围为87%-93%,P<0.004)。在体内条件下应用部分容积校正后,直径≥12.6 mm球体的¹²⁴I活度浓度测量的最大误差范围为±10%。
即使对于大结构,¹²⁴I PET定量也必须进行恢复校正。为确保准确的剂量测定,必须针对特定的PET扫描仪和要使用的放射性核素分别进行全面的绝对恢复测量。